RxDoctor Payments Data

Bryce Chiang, MD

Ophthalmology · Baltimore, MDNPI 1053816462

Payments from drug & device makers

$1,735in general payments, 2019–2025

Across 41 payments — averaging $42.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Sight Sciences, Inc.$192
  • Aerie Pharmaceuticals, Inc.$117
  • AbbVie$106
  • Glaukos Corporation$86
  • Nova Eye, Inc.$66
  • plus $123 from 4 others

What the payments were for

  • Food & beverage$1,735100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,735 in reported general payments places this provider in the 55th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$43,297
Medicare patients
85
Services billed
304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate56$28,196
LumiganBimatoprost58$25,619
CombiganBrimonidine Tartrate/Timolol32$13,382
VyzultaLatanoprostene Bunod24$12,497
Alphagan PBrimonidine Tartrate13$11,649
AzoptBrinzolamide17$10,172
Brimonidine Tartrate121$9,460
RocklatanNetarsudil Mesylat/Latanoprost23$9,165
Brinzolamide36$8,982
SimbrinzaBrinzolamide/Brimonidine Tart23$8,971
Timolol MaleateTimolol Maleate/Pf17$8,719
Travoprost36$8,696
RestasisCyclosporine14$7,633
ZioptanTafluprost/Pf17$5,879
Timolol Maleate264$5,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P, Restasis$106$58,283117 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$117$37,36179 claims
AlconAzopt, Simbrinza$1,045$19,14440 claims
Bausch & Lomb Americas Inc.Vyzulta$19$12,49724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →